Liquidia Corp (LQDA) is not a strong buy for a beginner, long-term investor at this moment. Despite strong revenue growth, the lack of positive trading signals, insider selling, and weak financial performance metrics such as declining net income and EPS suggest caution. Additionally, technical indicators and options data do not provide a compelling entry point for long-term investment.

Technical Analysis

The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 25.524, and moving averages are converging, showing no clear trend. The stock is trading near its S1 support level of 30.227, with resistance at 34.748. Overall, technical indicators suggest a weak trend with no strong buy signal.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low put-call ratios indicate bullish sentiment among options traders. However, implied volatility is high (158.69), suggesting significant uncertainty and risk.

Technical Summary

Sell

Buy

Positive Catalysts

Revenue growth of 1121.72% YoY in Q3 2025 and a gross margin increase to 94.16% (+45.26% YoY) indicate operational improvements.

Neutral/Negative Catalysts

Insider selling has increased significantly by 5672.87% over the last month, which is a bearish signal. Net income and EPS have dropped sharply (-84.74% and -86.67% YoY, respectively). No recent news or congress trading data to support positive sentiment.

Financial Performance

In Q3 2025, revenue increased significantly to $54.34M (+1121.72% YoY), but net income dropped to -$3.53M (-84.74% YoY), and EPS fell to -0.04 (-86.67% YoY). Gross margin improved to 94.16% (+45.26% YoY), indicating cost efficiency but poor profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target changes available for LQDA.

8 Analyst Rating

Wall Street analysts forecast LQDA stock price to rise

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 31.020

Low

Averages

47.5

High

Current: 31.020

Low

Averages

47.5

High

H.C. Wainwright

Buy

maintain

$35 -> $50

AI Analysis

2025-11-04

Reason

H.C. Wainwright

Price Target

$35 -> $50

AI Analysis

2025-11-04

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Liquidia to $50 from $35 and keeps a Buy rating on the shares. The firm says the company's profitability "arrived early" with Liquidia reporting "impressive" Q3 earnings. The investment story "has shifted from a binary launch to a profit driven story," the analyst tells investors in a research note.

Raymond James

Strong Buy

maintain

$41 -> $47

2025-11-04

Reason

Raymond James

Price Target

$41 -> $47

2025-11-04

maintain

Strong Buy

Reason

Raymond James raised the firm's price target on Liquidia to $47 from $41 and keeps a Strong Buy rating on the shares. Liquidia's Q3 earnings were driven by strong Yutrepia performance in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, with net sales of $51.7M, over triple consensus estimates, and profitability achieved ahead of schedule, the analyst tells investors in a research note. Yutrepia accounted for roughly 75% of revenue growth in its market, aided by major PBM contracts and easing new-patient restrictions. Unadjusted peak sales estimates have been raised to about $2B from $1.1B, reflecting exceptional early launch momentum.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LQDA

Unlock Now

LQDA Should I Buy

LQDA Should I Buy

Should You Buy Liquidia Corp (LQDA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch